VCM
BCRX icon

Voleon Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Voleon Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
+132,206
New +$1.2M 0.02% 422
2026
Q1 		– Sell
-52,345
Closed -$408K – 801
2025
Q4 		$408K Sell
52,345
-55,185
-51% -$399K 0.01% 617
2025
Q3 		$816K Buy
+107,530
New +$895K 0.02% 478

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Voleon Capital Management's BCRX Position: Q2 2026 in Review

Voleon Capital Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 132,206 shares worth $1.32M. The stake represents 0.02% of the portfolio and ranks #422 among its holdings. This is a return to the name: Voleon Capital Management previously reported a position in BCRX as recently as Q4 2025.

Voleon Capital Management first reported a position in BCRX in Q3 2025 and has held it in 3 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Voleon Capital Management held 132,206 shares of BioCryst Pharmaceuticals worth $1.32M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Voleon Capital Management position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.02% of Voleon Capital Management's portfolio in Q2 2026, its #422 holding.
  • Voleon Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.